NYSE:TFX

Stock Analysis Report

Executive Summary

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide.

Snowflake

Fundamentals

Moderate growth potential with questionable track record.


Similar Companies

Share Price & News

How has Teleflex's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.7%

NYSE:TFX

-0.08%

US Medical Equipment

0.2%

US Market


1 Year Return

51.0%

NYSE:TFX

14.1%

US Medical Equipment

-0.7%

US Market

TFX outperformed the Medical Equipment industry which returned 14.7% over the past year.

TFX outperformed the Market in United States of America which returned 0.3% over the past year.


Share holder returns

TFXIndustryMarket
7 Day-0.7%-0.08%0.2%
30 Day9.8%0.5%-2.7%
90 Day23.5%10.2%1.6%
1 Year51.7%51.0%15.0%14.1%1.6%-0.7%
3 Year105.5%102.0%68.4%63.2%40.0%30.9%
5 Year249.9%237.1%131.5%104.9%53.8%36.8%

Price Volatility Vs. Market

How volatile is Teleflex's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Teleflex undervalued based on future cash flows and its price relative to the stock market?

62.86x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Teleflex's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Teleflex's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Teleflex is overvalued based on earnings compared to the US Medical Equipment industry average.

Teleflex is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Teleflex is poor value based on expected growth next year.


Price Based on Value of Assets

Teleflex is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Teleflex expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

29.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Teleflex's revenue is expected to grow by 7.3% yearly, however this is not considered high growth (20% yearly).

Teleflex's earnings are expected to grow significantly at over 20% yearly.

Teleflex's revenue growth is positive but not above the United States of America market average.

Teleflex's earnings growth is expected to exceed the United States of America market average.

Teleflex's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Teleflex is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Teleflex performed over the past 5 years?

-2.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Teleflex's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.

Teleflex's 1-year earnings growth exceeds its 5-year average (199.8% vs -2.1%)

Teleflex's earnings growth has exceeded the US Medical Equipment industry average in the past year (199.8% vs 28.9%).


Return on Equity

Teleflex has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Teleflex used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Teleflex's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Teleflex's financial position?


Financial Position Analysis

Teleflex is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Teleflex's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Teleflex's level of debt (80.2%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (53.5% vs 80.2% today).

Debt is not well covered by operating cash flow (19.5%, less than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 5.4x coverage).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.6x debt.


Next Steps

Dividend

What is Teleflex's current dividend yield, its reliability and sustainability?

0.37%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Teleflex's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.48%).

Teleflex's dividend is below the markets top 25% of dividend payers in United States of America (3.83%).

Teleflex is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

Teleflex is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of Teleflex's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

No need to calculate the sustainability of Teleflex's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Teleflex's salary, the management and board of directors tenure and is there insider trading?

5.8yrs

Average management tenure


CEO

Liam Kelly (52yo)

1.6yrs

Tenure

US$6,108,486

Compensation

Mr. Liam J. Kelly has been Chief Executive Officer at Teleflex Incorporated since January 01, 2018 and has been its Director since May 4, 2018. Mr. Kelly has been the President at Teleflex Incorporated sin ...


CEO Compensation Analysis

Liam's remuneration is lower than average for companies of similar size in United States of America.

Liam's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

5.8yrs

Average Tenure

52yo

Average Age

The average tenure for the Teleflex management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

2.9yrs

Average Tenure

64yo

Average Age

The average tenure for the Teleflex board of directors is less than 3 years, this suggests a new board.


Insider Trading

Teleflex individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$147,30915 Aug 19
John Deren
EntityIndividual
Role
Chief Accounting Officer
VP & Chief Accounting Officer
Shares403
Max PriceUS$365.53
SellUS$990,97120 Jun 19
Stuart Randle
EntityIndividual
Role
Member of the Board of Directors
Director
Shares3,000
Max PriceUS$330.39
SellUS$110,27808 Mar 19
John Deren
EntityIndividual
Role
Chief Accounting Officer
VP & Chief Accounting Officer
Shares384
Max PriceUS$287.18
BuyUS$356,25008 Mar 19
John Heinmiller
EntityIndividual
Role
Member of the Board of Directors
Director
Shares1,250
Max PriceUS$285.00
SellUS$222,92620 Sep 18
Thomas Kennedy
EntityIndividual
Shares829
Max PriceUS$268.91

Ownership Breakdown


Management Team

  • Tom Powell (57yo)

    Executive VP & CFO

    • Tenure: 7.4yrs
    • Compensation: US$2.89m
  • Gwen Watanabe (47yo)

    Vice President of Global Corporate Development & Strategy

    • Tenure: 6.1yrs
  • James Leyden (52yo)

    VP, General Counsel & Secretary

    • Tenure: 5.5yrs
    • Compensation: US$1.45m
  • Dave Amerson

    President & GM of Interventional Urology

    • Tenure: 0.0yrs
  • Jake Elguicze (46yo)

    VP of Investor Relations & Treasurer

    • Tenure: 0.0yrs
  • Liam Kelly (52yo)

    President

    • Tenure: 1.6yrs
    • Compensation: US$6.11m
  • Gwen Chapman (44yo)

    Chief Compliance Officer & VP

    • Tenure: 0.0yrs
  • Cam Hicks (54yo)

    VP of Global Human Resources & Employee Communications

    • Tenure: 6.3yrs
    • Compensation: US$1.13m
  • John Deren

    VP & Chief Accounting Officer

    • Tenure: 2.3yrs
  • Tim Duffy

    Chief Information Officer & VP

    • Tenure: 0.0yrs

Board Members

  • George Babich (67yo)

    Lead Director

    • Tenure: 0.0yrs
    • Compensation: US$278.45k
  • John Heinmiller (64yo)

    Director

    • Tenure: 0.6yrs
  • Gretchen Frances Haggerty (63yo)

    Director

    • Tenure: 2.9yrs
    • Compensation: US$239.40k
  • Richard Packer (61yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: US$239.40k
  • Benson Smith (71yo)

    Chairman of the Board

    • Tenure: 8.6yrs
    • Compensation: US$318.31k
  • Stu Randle (59yo)

    Director

    • Tenure: 10.3yrs
    • Compensation: US$259.40k
  • Andy Krakauer (64yo)

    Director

    • Tenure: 1.6yrs
    • Compensation: US$372.08k
  • Stephen Klasko (65yo)

    Independent Director

    • Tenure: 11.3yrs
    • Compensation: US$236.40k
  • Candace Duncan (66yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: US$246.06k
  • Liam Kelly (52yo)

    President

    • Tenure: 1.6yrs
    • Compensation: US$6.11m

Company Information

Teleflex Incorporated's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Teleflex Incorporated
  • Ticker: TFX
  • Exchange: NYSE
  • Founded: 1943
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$17.007b
  • Shares outstanding: 46.23m
  • Website: https://www.teleflex.com

Number of Employees


Location

  • Teleflex Incorporated
  • 550 East Swedesford Road
  • Suite 400
  • Wayne
  • Pennsylvania
  • 19087
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TFXNYSE (New York Stock Exchange)YesCommon SharesUSUSDJan 1968
TBHDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 1968

Biography

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offe ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 23:48
End of Day Share Price2019/08/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.